Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Pharming het aandeel van 2017
Volgen
Exact wat ik votige week al vertelde,dat de vries geen haast had met het indienen. Hij maakt gebruik van de tekorten dus artsen gaan zelf ruconest voorschrijven voor profilactisch gebruik. Ooooo wat een slimme man zeg ik had hem door.
steel engineer schreef op 10 oktober 2017 08:40 :
Betekent onderstaande dat Ruconest slechts uitzonderlijk wordt toegediend?
"5. Must have documentation of therapeutic failure or severe adverse reaction to Berinert or Firazyr"
Goede opmerking. Berinert mag maar beperkt worden toegediend, enkel specifieke delen van het lichaam toch? @jandekkerrs Heb je ook de criteria van Berinert? En Cinryze?
moneymaker_BX schreef op 10 oktober 2017 08:50 :
Kan iemand mij ff bijpraten?
Wat was HET GROTE nieuws de laatste 18 uur waardoor iedereen zo positief klinkt hedenochtend
Onno van galapagos was jarig
BePositive schreef op 10 oktober 2017 08:54 :
[...]
Onno van galapagos was jarig
Humor!
Fda zal deze patiënten goed volgen en als de werking goed is kassa voor pharming, en natuurlijk alle pharming beleggers. Ook deze patienten gaan niet weer overstappen als het product goed werkt.
Nou het valt weer terug..
Dat was het dan denk ik niet veel effect gehad op dit moment
weveka schreef op 10 oktober 2017 08:53 :
Ben benieuwd of de move van gisterenmiddag een schijnbeweging was of niet !
Er is geen echt nieuws, dus.... dobbelstenen erbij pakken maar.
Kwam even roestig uit de startblokken maar heeft de weg UP nu wel gevonden!
En daar gaat het beginnen riemen vast
Mensen wat was het nieuws nou? Gaarne
KarenT geen handel vandaag?
Uiteraard, grote belangstelling dus mooie daytrades
Ruconest word de "standard-care" voor Hae,rest word niet meer vergoed door Providers,tenminste ten dele,zou zo maar kunnen gebeuren,
Pharming nadert de weerstand 0,81. De trend van Pharming blijft ondanks de huidige consolidatiefase nog steeds opwaarts gericht. De hogere bodems wijzen nog steeds op aanhoudende vraag. De steun ligt rond 0,44 (bodem van 6 september). Slaagt Pharming erin om boven de laatste top te breken, dan kan de stijgende trend weer worden hervat en komt er ruimte vrij voor verdere koersstijging. Weerstand hanteren we op 0,81 (top van 26 maart 2012). Na een uitbraak boven weerstand 0,81 wordt 0,85 het volgende opwaartse koersdoel.
Geel driehoekje met uitroepteken voor mmbx, dat wordt het nieuws.
lower schreef op 10 oktober 2017 08:54 :
[...]
Goede opmerking.
Berinert mag maar beperkt worden toegediend, enkel specifieke delen van het lichaam toch?
@jandekkerrs
Heb je ook de criteria van Berinert? En Cinryze?
Pharmacy Management Drug Policy SUBJECT: Hereditary Angioedema (HAE) For Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Ruconest POLICY NUMBER: Pharmacy-19 EFFECTIVE DATE: 8/11 LAST REVIEW DATE: 9/29/2017 If the member’s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. Medical or drug policies apply to commercial and Health Care Reform products only when a contract benefit for the specific service exists. Proprietary of the Insurance Plan Page 1 of 7 DESCRIPTION: Hereditary angioedema (HAE) is an autosomal dominant disease that is caused by a deficiency in functional C1 esterase inhibitor, which leads to increases in bradykinin levels. The increase in bradykinin produces an increase in vascular permeability which leads to episodes of nonpruritic, nonpitting, subcutaneous or submucosal edema. Symptoms involve the arms, legs, hands, feet, bowels, genitalia, trunk, face, tongue, or larynx and typically begin in early childhood (2-3 years of age). Attacks can be precipitated by minor trauma and stress, but may occur without an apparent trigger. The following are measured to help confirm a diagnosis of HAE. • Serum complement factor 4 (C4) • C1 inhibitor (C1-INH) antigenic protein • C1 inhibitor (C1-INH) functional level HAE is classified into two main subtypes, Individuals with Subtype I have documented low levels of C4, C1-INH protein and C1-INH functional activity. Individuals with Subtype II have normal levels of C1-INH protein but low levels of C4 and C1-INH function. Treatment guidelines also acknowledge HAE with normal C1-INH (Subtype III) in which the C4, C1-INH protein and C1-INH functional activity are all normal. HAE can be treated by Berinert (Human C1 Esterase Inhibitor), Cinryze (Human C1 Esterase Inhibitor), Haegarda (Human C1 Esterase Inhibitor), Kalbitor (Ecallantide), Firazyr (Icatibant) or Ruconest (Recombinant C1 Esterase Inhibitor) each of which is FDA approved to reduce edema symptoms. Berinert, Cinryze, Haegarda, and Ruconest treat HAE by replacing Human C1 Esterase Inhibitor deficiencies. Kalbitor treats HAE attacks by inhibiting plasma kallkrein which cleaves high molecular weight kininogen and results in bradykinin release. Firazyr inhibits bradykinin from binding the B2 receptor. POLICY: Based upon our assessment and review of the peer-reviewed literature Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, and Ruconest have been medically proven to be effective and therefore, medically necessary for the prophylactic and acute attack treatment of Hereditary Angioedema (HAE) following diagnoses if specific criteria are met: A. To be considered for drug treatment, individuals must have a confirmed diagnosis of HAE based on the following: 1. Type 1 HAE a. Two separate measurements indicating decreased quantities of C4 and C1-INH and a history of angioedema OR Pharmacy Management Drug Policy Hereditary Angioedema (HAE) Proprietary of the Insurance Plan Page 2 of 7 2. Type II HAE b. If low C4 quantity but C1-INH protein normal then determine C1-INH function and repeat C4 and C1-INH. Decreased levels of C4 and C1-INH function confirms a diagnosis of Type II HAE OR 3. HAE with normal C1-INH (Type III HAE) a. Individuals with normal levels of C4 and C1-INH both during an attack and at baseline are classified as Type III HAE. Patient must have a family history of angioedema along with documented evidence that shows: 1. Treatment with high doses of the antihistamine cetirizine at 40 milligrams a day (or equivalent) for 1 month was not effective OR 2. Demonstration of a Factor XII mutation that is associated with the disease AND 4. Medications known to cause angioedema (i.e. ACE-Inhibitors, estrogens, angiotensin II receptor blockers) have been evaluated and discontinued when appropriate, regardless of HAE type AND 5. Medication must be prescribed by an allergist, immunologist, hematologist or dermatologist B. Berinert specific criteria 1. Must have a diagnosis of acute abdominal or facial attacks associated with hereditary angioedema (progress notes required) 2. Must be used for acute attacks--Safety and efficacy as prophylactic therapy has not been established and therefore will not be covered 3. Berinert has been proven to be both safe and effective in adult and pediatric patients 4. Berinert will be reviewed under the medical benefit when administered by a health care professional. If the member transitions to self-administration then Berinert can be authorized under the pharmacy benefit. 5. Dose is 20 units per kg by IV infusion. a. Maximum quantity limit of 10 vials per 30 days on Rx benefit b. Authorization on the medical benefit will be for 1 month initially then every 6 months c. Authorization on the pharmacy benefit will be for 6 months at a time d. Recertification will require documentation of decrease in severity or duration of attacks. Documentation including frequency of administration will also be required at time of recertification to monitor for appropriate use. C. Kalbitor specific criteria 1. Must have a diagnosis of acute abdominal or facial attacks associated with hereditary angioedema (progress notes required) 2. Must be used for acute attacks--Safety and efficacy as prophylactic therapy has not been established and therefore will not be covered 3. Safety and efficacy has not been established in children under the age of 12 and therefore will not be covered 4. Anaphylaxis has been reported after administration of Kalbitor. Because of the risk of anaphylaxis, it should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and HAE and is therefore covered under the medical benefit.
Wat me opvalt is dat grote biedblokken van b.v. 400.000 of zoals net 200.000 onmiddellijk ingelost worden, dus er wordt ook aardig verkocht.
Alle riemen vast houden aub....
lower schreef op 10 oktober 2017 08:54 :
[...]
Goede opmerking.
Berinert mag maar beperkt worden toegediend, enkel specifieke delen van het lichaam toch?
@jandekkerrs
Heb je ook de criteria van Berinert? En Cinryze?
Pharmacy Management Drug Policy Hereditary Angioedema (HAE) Proprietary of the Insurance Plan Page 3 of 7 5. Must have documentation of therapeutic failure or severe adverse reaction to Berinert or Firazyr 6. The recommended dose of KALBITOR is 30 mg (3 mL), administered subcutaneously in three 10 mg (1mL) injections. If the attack persists, an additional dose of 30 mg may be administered within a 24 hour period. 7. Authorization will be for 1 month initially then every 6 months a. Recertification will require documentation of decrease in severity or duration of attacks. Documentation including frequency of administration will also be required at time of recertification to monitor for appropriate use D. Cinryze specific criteria 1. Must have a diagnosis of hereditary angioedema (progress notes required) 2. Must be used as a prophylaxis – not for acute treatment 3. For long term prophylaxis, the patient must meet the following: a. History of at least two severe HAE attacks (i.e. airway swelling, debilitating cutaneous or gastrointestinal episodes) per month that resulted in loss of work/school productivity or ER/unscheduled doctor visits OR disability for > 5 days per month due to HAE AND b. Patient has a documented contraindication, severe intolerance, or therapeutic failure to 17 alpha-alkylated androgens (e.g. danazol) for HAE prophylaxis AND c. Treatment with acute therapy (i.e. Kalbitor, Firazyr, Berinert or Ruconest) did not result in meaningful outcomes such as decreased severity of attacks, avoidance of hospitalization, etc 4. Requests for new start of Cinryze will require documentation of therapeutic failure, severe intolerance or a contraindication to Haegarda. 5. Cinryze will be allowed for short-term prophylaxis if being requested prior to medical, surgical or dental procedure. Approval will be for one month only. 6. Cinryze will be reviewed under the medical benefit when administered by a health care professional. If the member transitions to self-administration, then Cinryze can be authorized under the pharmacy benefit. 7. Standard dosage is 1000 unit IV infusion over 10 minutes every 3-4 days. 8. There is a quantity limit of 20 vials per 30 days. a. Requests for quantities in excess of the establish quantity limit, will be considered based on Cinryze package labeling that states: For patients who have not responded adequately to 1000 unit every 3 or 4 days, doses up to 2500 unit (not exceeding 100 U/kg) every 3 or 4 days may be considered based on individual patient response. b. Requests will require documentation of a previous trial with the standard dosage (1000 unit) and outcome of the trial, to document the need for the increased dose. c. No more than 50 vials per 30 days will be authorized. 9. Authorization on either the medical benefit or the pharmacy benefit will be for 6 months. i. Recertification will require documentation of decrease in the severity, duration, and/or frequency of attacks. Documentation including frequency of administration will also be required at time of recertification to monitor for appropriate use 10.Safety and efficacy in children under the age of 13 has not been established and therefore will not be covered
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)